N-[2-(7-phenyl-1,6-dihydro-2H-indeno[5,4-b]furan-8-yl)-ethyl]acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: N-[2-(7-phenyl-1,6-dihydro-2H-indeno[5,4-b]furan-8-yl)-ethyl]acetamide
• 英文别名: N-[2-(7-phenyl-1,6-dihydro-2H-indeno[5,4-b]furan-8-yl)ethyl]acetamide；N-[2-(7-phenyl-2,6-dihydro-1H-cyclopenta[e][1]benzofuran-8-yl)ethyl]acetamide
• 化学式: C₂₁H₂₁NO₂
• 分子量: 319.403
• InChiKey: UIGUZEMEJLIGSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ylidene)acetonitrile 在 盐酸 、 四(三苯基膦)钯 、 氨 、 氢气 、 溴 、 sodium carbonate 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 甲苯 为溶剂， 反应 76.17h， 生成 N-[2-(7-phenyl-1,6-dihydro-2H-indeno[5,4-b]furan-8-yl)-ethyl]acetamide
  参考文献：
  名称：

  1,6-Dihydro-2H-indeno[5,4-b]furan Derivatives: Design, Synthesis, and Pharmacological Characterization of a Novel Class of Highly Potent MT₂-Selective Agonists

  摘要：

  A novel series of 1,6-dihydro-2H-indeno[5,4-b]furan derivatives were designed and synthesized as MT2-selective ligands. This scaffold was identified as a potent mimic of the 5-methoxy indole core of melatonin, and introduction of a cyclohexylmethyl group at the 7-position of this scaffold afforded an MT2-selective ligand 15 (K-i = 0.012 nM) with high MT1/MT2 selectivity (799). Compound 15 was identified as a potent full agonist for the MT2 subtype and exhibited reentrainment effects to a new light/dark cycle in ICR mice at 3-30 mg/kg. This result demonstrated the involvement of the MT2 receptors in chronobiotic activity.

  DOI：

  10.1021/jm200221q

文献信息

• Tricyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06034239A1

  公开（公告）日：2000-03-07

  A compound of the formula: ##STR1## wherein R.sup.1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R.sup.2 is H or an optionally substituted hydrocarbon group; R.sup.3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR.sup.4, NR.sup.4, O or S in which R.sup.4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.

  该化合物的结构式为：##STR1## 其中R.sup.1是可选择取代的碳氢化合物、氨基或杂环基团；R.sup.2是H或可选择取代的碳氢基团；R.sup.3是H或可选择取代的碳氢或杂环基团；X是CHR.sup.4、NR.sup.4、O或S，其中R.sup.4是H或可选择取代的碳氢基团；Y是C、CH或N；环A是可选择取代的5-至7-成员环；环B是可选择取代的苯环；m为1至4，或其盐，提供了其制备方法、生产中间体和包含它的药物组合物。
• Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1199304A1

  公开（公告）日：2002-04-24

  A compound having the following general fomula: wherein R1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R2 is H or an optionally substituted hydrocarbon group; R3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR4, NR4, O or S in which R4 is H or an optionally substituted hydrocarbon group; R5 is H, a halogen atom, C1-6 alkyl group, a C1-6 alkoxy group, a hydroxy group, a nitro group, a cyano group or an amino group wherein the C1-6 alkyl group, the C1-6 alkoxy group and the amino group may be substituted by 1 to 5 substituents, Y is C or N; ring B is an optionally substituted benzene ring; m = 1 to 4 and n = 0 to 2; L represents a leaving group such as a halogen atom, an alkylsulfonyl group, an alkylsulfonlyoxy group and arylsulfonyloxy group; or a salt thereof.

  具有以下一般式的化合物： 其中R1是可选择取代的碳氢化合物、氨基或杂环基团；R2是H或可选择取代的碳氢基团；R3是H或可选择取代的碳氢基团或杂环基团；X是CHR4、NR4、O或S，其中R4是H或可选择取代的碳氢基团；R5是H、卤素原子、C1-6烷基基团、C1-6烷氧基团、羟基、硝基、氰基或氨基，其中C1-6烷基基团、C1-6烷氧基团和氨基可能被1至5个取代基取代，Y是C或N；环B是可选择取代的苯环；m = 1至4，n = 0至2；L代表离去基团，如卤素原子、烷基磺酰基团、烷基磺酰氧基团和芳基磺酰氧基团；或其盐。
• Bicyclic intermediates
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1550655A1

  公开（公告）日：2005-07-06

  A compound having the following general fomula: wherein R1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R2 is H or an optionally substituted hydrocarbon group; R3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR4, NR4, O or S in which R4 is H or an optionally substituted hydrocarbon group; R5 is H, a halogen atom, C1-6 alkyl group, a C1-6 alkoxy group, a hydroxy group, a nitro group, a cyano group or an amino group wherein the C1-6 alkyl group, the C1-6 alkoxy group and the amino group may be substituted by 1 to 5 substituents, Y is C or N; ring B is an optionally substituted benzene ring; m = 1 to 4 and n = 0 to 2; L represents a leaving group such as a halogen atom, an alkylsulfonyl group, an alkylsulfonlyoxy group and arylsulfonyloxy group; or a salt thereof.

  具有以下通式的化合物： 其中 R1 是任选取代的烃基、氨基或杂环基； R2 是 H 或任选取代的烃基； R3 是 H 或任选取代的烃基或杂环基； X 是 CHR4、NR4、O 或 S，其中 R4 是 H 或任选取代的烃基；R5 是 H、卤素原子、C1-6 烷基、C1-6 烷氧基、羟基、硝基、氰基或氨基，其中 C1-6 烷基、C1-6 烷氧基和氨基可被 1 至 5 个取代基取代，Y 是 C 或 N；环 B 是任选取代的苯环；m = 1 至 4，n = 0 至 2；L 代表离去基团，如卤素原子、烷基磺酰基、烷基磺酰氧基和芳基磺酰氧基；或其盐。
• Tricylic compounds having binding affinity for melatonin receptors, their production and use
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP0885210B2

  公开（公告）日：2008-06-18
• US6034239A
  申请人：——

  公开号：US6034239A

  公开（公告）日：2000-03-07